UPCOMING EVENTS & DEADLINES
For more photonics conference, check out these sites.
-
RT @laura_chmbre: New research article with @LabSanyal just published in @BioconjChem: Surfactant-Free Direct Access to Porphyrin-Cro… https://t.co/9e9aCo5Bra -
RT @ucl_discovery: Open Access UCL Research: Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Del… https://t.co/PmDSAxXX1n
-
RT @MichaelHamblin3: Another paper in Nature Scientific Reports about antimicrobial photodynamic inactivation using tetracyclines as pho… https://t.co/bq79V0U3Nb
-
Ondine President is Key Speaker at Royal Society of Medicine (RSM) 2018 PDT Symposium https://t.co/Rb5Zq4nSxB @OndineBio
-
RT @NCICCR_UroOnc: Review (and cover photo) from @minerva_marie @Agarwal_CaB on Photodynamic Therapy for Bladder Cancer @EurUrolFocus… https://t.co/cZNJcLRqxj
-
RT @EPICassoc: Modulight becomes exclusive supplier for BAUSCH + LOMB! They announced the companies have entered into an exclusive… https://t.co/ERdGcvwPru
-
RT @Pharmaceut_MDPI: Special Issue Open for Submission “Photodynamic Therapy 2019“ Guest edited by Prof. Serge Mordon… https://t.co/EZsfcbYv8A
-
Silk fibroin hydrogels for potential applications in photodynamic therapy - Rojas - - Biopolymers - Wiley Online Li… https://t.co/kJngAMxFGZ
-
Photodynamic Therapy: Targeting Cancer with Light https://t.co/IPCmI38n9c
International Photodynamic Association (IPA)
The IPA was founded in 1986 with membership consisting of prominent international scientists, health care professionals, students, and fellows researching photodynamic therapy (PDT) and photodiagnosis (PD). The IPA's purpose is to promote the study of diagnosis and treatment using light activated photosensitisers and to disseminate scientific information to its members, the research community, and to the community at large. The IPA organizes a Biennial World Congress, providing a unique opportunity to share data and listen to cutting edge discoveries surrounding PDT.
Please join us for the
Bringing together researchers and clinicians in all fields of photodynamic therapy (PDT) and photodiagnosis (PD) since 1986. Every two years, the IPA organizes a conference to foster scientific development and contribute to clinical practice. The 17th IPA World Congress in conjunction with SPIE will be in Cambridge, MA from June 28 - July 4, 2019. We welcome you to Boston in 2019.
Conference Chair: Tayyaba Hasan, PhD - Professor at the Wellman Center for Photomedicine, Harvard Medical School and a Professor of Health Sciences and Technology (Harvard-MIT).
WHAT IS PDT and PD?
Photodynamic therapy (PDT) employs light-sensitive compounds known as photosenstizers (PSs) that when exposed selectively to light in conjunction with molecular oxygen become toxic to cells resulting in cell death. Many PSs exist today including: cationic dyes such as methylene blue, tetrapyrrole derivatives (phthalocyanines, chlorins, porphyrins), chlorophyll derivatives, and functionalized fullerenes.
PDT, a minimally invasive treatment option, is used to treat many conditions including: acne, psoriasis, age related macular degeneration, and several cancers such as skin, lung, brain, bladder, bile-duct, esophageal, and head and neck cancers. PDT is also proven to eradicate pathogenic microorganisms Gram-positive and Gram-negative bacteria, yeasts and fungi.
Photodiagnosis (PD), also known as Photodynamic Diagnosis (PDD) is the use of light-sensitive compounds to indicate the presence of cancerous or diseased tissue. The same photosensitizers that are used for the treatment of cancer can also assist in its diagnosis. The emitted fluorescence from the activated photosensitizer can be used to differentiate cancerous from normal tissue guiding physicians during surgical resection.
To learn more about the basics of photomedicine, the American Society for Photobiology (ASP) has a great free resource available on line.
